22
Participants
Start Date
March 31, 2010
Primary Completion Date
April 30, 2013
Study Completion Date
December 31, 2014
recombinant human growth hormone (rhGH)
Initial rhGH dose 0.4mg administered by subcutaneous injection daily. Dose will be increased to 0.6 mg after one week and then increased to 0.8mg after two weeks.
Placebo
Placebo will be administered by daily subcutaneous injections. Sham increases will be used.
Massachusetts General Hospital, Boston
Collaborators (1)
Genentech, Inc.
INDUSTRY
Massachusetts General Hospital
OTHER